They share overlapping clinical, cytomorphologic, and immunophenotypic features, posing difficulties in the reliable distinction between the splenic B-cell lymphomas and leukaemias, except for HCL harboring the characteristic BRAF p.V600E mutation. Here, BRAF is linked to leukemia.